A Review on Uses of Various Nanoparticlesin the Treatment of Rheumatoid Arthritis
Asian Journal of Pharmaceutical Research and Development · 2022
DOI: 10.22270/ajprd.v10i1.1073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Journal of Pharmaceutical Research and Development, 2022. Verfasst von Shriram Bairagi und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is a most common autoimmune (auto-self: immune-immunity system). It is inflammatory in nature. If generally causes bone and cartilage destruction. Itaffect on joint clinical manifestationsof arthritis various from patient to patient. Now, new field comes into existence called use of nanoparticles and nanotechnology. It improves the pharmacokinetic as well as pharmacodynamics of rheumatoid arthritis drugs. Nanoparticles act on site of inflammation and delivery of therapeutic agent to that site. It also increases specificity of drugs and decrease side effects. These review summarize the current therapeutic strategies for rheumatoid arthritis. Nanotechnology or nanoparticles used in treatment of rheumatoid arthritis. Mostly focus on application of nanoparticles in treatment of rheumatoid arthritis.
Zitieren
APA
Bairagi, S., Takarkhede, S., Dighe, J., & Gangurde, D. (2022). A Review on Uses of Various Nanoparticlesin the Treatment of Rheumatoid Arthritis. Asian Journal of Pharmaceutical Research and Development. https://doi.org/10.22270/ajprd.v10i1.1073
Vancouver
Bairagi S, Takarkhede S, Dighe J, Gangurde D. A Review on Uses of Various Nanoparticlesin the Treatment of Rheumatoid Arthritis. Asian Journal of Pharmaceutical Research and Development. 2022. doi:10.22270/ajprd.v10i1.1073
BibTeX
@article{Bairagi2022,
author = {Bairagi, Shriram and Takarkhede, Smita and Dighe, Jagruti and Gangurde, Dhaneshwari},
title = {A Review on Uses of Various Nanoparticlesin the Treatment of Rheumatoid Arthritis},
journal = {Asian Journal of Pharmaceutical Research and Development},
year = {2022},
doi = {10.22270/ajprd.v10i1.1073}
}
EUVIMED